The purpose of this study is to determine the proportion of positive ctDNA in patients with pancreatic cancer. This study investigates the relationship between ctDNA biomarkers and patient survival.
This study evaluates the role of serial ctDNA analysis as a biomarker in patients undergoing treatment for resectable pancreatic cancer. It looks at ctDNA's potential in predicting patient outcomes.
- Who can participate: Adults aged 18 and older with newly diagnosed resectable or borderline resectable pancreatic cancer may participate. Candidates must have a life expectancy of at least 6 months and be able to provide informed consent.
- Study details: Participants will undergo regular treatment for pancreatic cancer, which may include chemotherapy, chemo-radiation, and surgery. Blood samples will be collected for ctDNA detection. A placebo is not used in this study.